Search
Citations & References (5)
Gibco™
CTS™ OpTmizer™ T Cell Expansion SFM, bag format
Gibco™ OpTmizer™ CTS™ T-Cell Expansion SFM has been developed for the growth and expansion of human T lymphocytes. OpTmizer™ CTS™Read more
| Catalog Number | Quantity |
|---|---|
| A1048503 | 1 Bag |
Catalog number A1048503
Price (EUR)
243,00
Each
Quantity:
1 Bag
Price (EUR)
243,00
Each
Gibco™ OpTmizer™ CTS™ T-Cell Expansion SFM has been developed for the growth and expansion of human T lymphocytes. OpTmizer™ CTS™ T-Cell Expansion medium is a complete serum-free and xeno-free 1X medium consisting of OpTmizer™ T-Cell Expansion Basal Medium (1 L bag) and OpTmizer™ T-Cell Expansion Supplement (26 mL), which are mixed together prior to use.
• Maintains similar phenotype and function as T-cells cultured in conventional serum supplemented medium
• Consistent performance in supporting T-cell expansion
• Supports high density cultures in static and WAVE Bioreactor™ cultures
• Be ready for clinical research with this cGmP manufactured formula and support documentation
Versatile T Cell Culture Media
OpTmizer™ CTS™ T-Cell Expansion SFM is designed to give results equivalent to conventional serum-supplemented media. However, if desired, 2% heat-inactivated human serum (Cat. No. 34005-100) may be added to the medium to enhance viability and expansion. The use of serum, and the amount required, should be determined empirically depending on the specific T-cell culture application.
Ready for T Cell Expansion
OpTmizer™ CTS™ T-Cell Expansion SFM is designed for the expansion of human T-cells permitting CD3+ densities of >3x106 cells/mL in static conditions and >2x107 cells/mL in WAVE bags. Results may vary depending on the T-cell subset (e.g., Ag-specific cells). Conditions for specific T-cell culture applications should be determined empirically.
Stability of Complete Media
Complete OpTmizer™ CTS™ T-Cell Expansion SFM (basal, supplement, and L-glutamine) is stable for 4 weeks when stored in the dark at 2–8°C.
Simplify Your Transition into Clinical Research
The Gibco™ Cell Therapy Systems (CTS™) brand offers a broad array of products for use in cell therapy applications, including media, reagents, growth factors, enzymes, cell selection/expansion reagents, and devices. Gibco™ CTS™ products deliver:
• Reduced burden in qualifying reagents
• Appropriate certificates of analyses and origin included
• Convenient access to our Drug Master File (DMF)
• Maintains similar phenotype and function as T-cells cultured in conventional serum supplemented medium
• Consistent performance in supporting T-cell expansion
• Supports high density cultures in static and WAVE Bioreactor™ cultures
• Be ready for clinical research with this cGmP manufactured formula and support documentation
Versatile T Cell Culture Media
OpTmizer™ CTS™ T-Cell Expansion SFM is designed to give results equivalent to conventional serum-supplemented media. However, if desired, 2% heat-inactivated human serum (Cat. No. 34005-100) may be added to the medium to enhance viability and expansion. The use of serum, and the amount required, should be determined empirically depending on the specific T-cell culture application.
Ready for T Cell Expansion
OpTmizer™ CTS™ T-Cell Expansion SFM is designed for the expansion of human T-cells permitting CD3+ densities of >3x106 cells/mL in static conditions and >2x107 cells/mL in WAVE bags. Results may vary depending on the T-cell subset (e.g., Ag-specific cells). Conditions for specific T-cell culture applications should be determined empirically.
Stability of Complete Media
Complete OpTmizer™ CTS™ T-Cell Expansion SFM (basal, supplement, and L-glutamine) is stable for 4 weeks when stored in the dark at 2–8°C.
Simplify Your Transition into Clinical Research
The Gibco™ Cell Therapy Systems (CTS™) brand offers a broad array of products for use in cell therapy applications, including media, reagents, growth factors, enzymes, cell selection/expansion reagents, and devices. Gibco™ CTS™ products deliver:
• Reduced burden in qualifying reagents
• Appropriate certificates of analyses and origin included
• Convenient access to our Drug Master File (DMF)
Specifications
Cell TypeT Cells
Culture EnvironmentCO2
Endotoxin LevelVery Low
Included AntibioticsNo antibiotics
Inorganic SaltsCalcium, Magnesium
Product TypeCell Expansion Serum Free Medium (SFM)
Purity or Quality GradeResearch Grade
Quantity1 Bag
ClassificationChemically-defined, Serum-free, Xeno-free
Culture TypeSuspension Cell Culture
FormLiquid
Serum LevelSerum-free
SterilitySterile
With AdditivesHEPES, Phenol Red, Sodium Pyruvate, Sodium Bicarbonate
Without AdditivesNo Glutamine
Unit SizeEach
Contents & Storage
OpTmizer™ T-Cell Expansion Basal Medium (1 x L media bag): Store at 2–8°C. Protect from light.
OpTmizer™ T-Cell Expansion Supplement (1 x 26 mL): Store in the dark at 2–8°C.
OpTmizer™ T-Cell Expansion Supplement (1 x 26 mL): Store in the dark at 2–8°C.
Frequently asked questions (FAQs)
What is CTS?
Do I need to order additional components with the CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503)?
Will CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) work with all types of T cells?
Can CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) be used for animal T cell cultures other than human?
Is there a difference in formulation of the CTS OpTmizer T Cell Expansion SFM between the bottle and bag packaging formats?
Citations & References (5)
Citations & References
Abstract
Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.
Journal:
PubMed ID:25671129
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens
Bioengineering and serum free expansion of blood-derived ?d T cells.
Journal:Cytotherapy
PubMed ID:27260209
'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
Journal:Hum Gene Ther Methods
PubMed ID:27897048
The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps,
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Journal:Vaccine
PubMed ID:28536029
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported the rationale for a phase I clinical trial where safety,
Enhancing adoptive cancer immunotherapy with V?2Vd2 T cells through pulse zoledronate stimulation.
Journal:J Immunother Cancer
PubMed ID:28239463
Human ?d T cells expressing V?2Vd2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with V?2Vd2 T cells has been used to treat cancer patients with partial and complete remissions. Most clinical trials and preclinical studies have